The association between blood glucose and oxidized lipoprotein(a) in healthy young women by Kotani, Kazuhiko et al.
SHORT PAPER Open Access
The association between blood glucose and
oxidized lipoprotein(a) in healthy young women
Kazuhiko Kotani
1*, Shingo Yamada
2, Shuumarjav Uurtuya
1, Toshiyuki Yamada
1, Nobuyuki Taniguchi
1,
Ikunosuke Sakurabayashi
3
Abstract
Background: Oxidized lipoproteins play important roles in the atherosclerotic processes. Oxidized lipoprotein(a)
(oxLp(a)) may be more potent in atherosclerotic pathophysiology than native Lp(a), a cardiovascular disease-
relevant lipoprotein. Increased blood glucose concentrations can induce oxidative modification of lipoproteins. The
aim of this study was to investigate the association between circulating oxLp(a) and cardiometabolic variables
including blood glucose in healthy volunteers within the normal range of blood glucose.
Methods: Several cardiometabolic variables and serum oxLp(a) (using an ELISA system) were measured among
70 healthy females (mean age, 22 years).
Results: Lp(a) and glucose were significantly and positively correlated with oxLp(a) in simple correlation test.
Furthermore, a multiple linear regression analysis showed oxLp(a) to have a weakly, but significantly positive and
independent correlation with only blood glucose (b = 0.269, P < 0.05).
Conclusions: These results suggest that increased glucose may enhance the oxidization of Lp(a) even at normal
glucose levels.
Background
Oxidized lipoproteins, such as oxidized low-density lipo-
protein (oxLDL), are involved in the atherosclerotic pro-
cesses [1]. Lipoprotein(a) (Lp(a)) contains low-density
lipoprotein (LDL)-like moieties, in which the apoB-100
component is covalently linked to the unique glycopro-
tein apolipoprotein(a) (apo(a)), and it is also a risk factor
for cardiovascular disease (CVD) [2,3]. Oxidized Lp(a)
(oxLp(a)) has been observed in human atherosclerotic
sites in arteries and blood [4]. Earlier experimental stu-
dies have shown that oxLp(a) can add specific athero-
genic properties to native Lp(a) [5-10]. On the other
hand, there are few clinical studies on oxLp(a) [4,11,12].
This is, in part, due to the lack of specific assays that
can be easily used in clinical settings. A few different
ELISA systems to detect circulating oxLp(a) have been
reported with limited clinical findings [4,11,12]. In one
assay system developed by us, complicated hypertensives
showed higher serum oxLp(a) levels than normotensives,
despite the fact that there was no difference in native Lp
(a) levels between hypertensives and normotensives [4].
In another assay system, the patients with end-stage
renal disease treated with continuous ambulatory perito-
neal dialysis demonstrated higher plasma oxLp(a) levels
than those without renal disease [11]. In an additional
assay system, the CVD patients exhibited higher plasma
levels than the healthy volunteers [12]. Taken together
experimental findings, oxLp(a) may be more potent than
native Lp(a) in atherosclerotic pathophysiology. Accu-
mulating in vivo evidence to elucidate the significance of
oxidization in Lp(a) is therefore crucial in better under-
standing the mechanistic roles of Lp(a) and oxLp(a) on
atherogenesis.
Reactive oxygen species have been shown to occur in
relatively high blood glucose concentrations, and the
oxidative stress promotes glycation-linked oxidative
modification of lipoproteins [13,14]. This can result in
the vascular damage; thus, the relationship between glu-
cose and oxidized lipoproteins is of interest. This study
examined the association between blood concentrations
of oxLp(a) and cardiometabolic variables including
glucose among healthy subjects.
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A total of 70 Japanese young women (mean age; 22.2
years, range; 18-26 years) were enrolled in this study.
The eligibility criteria were: 1) within normal fasting
plasma glucose levels (< 5.56 mmol/L) and without a
history of diabetes mellitus, 2) without obesity (body
mass index [BMI] < 25 kg/m
2), hypertension (systolic/
diastolic blood pressure [SBP/DBP] < 140/90 mmHg)
and lipid abnormality (LDL-cholesterol [LDL-C] < 3.64
mmol/L, triglyceride [TG] < 1.7 mmol/L or high-density
lipoprotein-cholesterol [HDL-C] > 1.04 mmol/L), 3)
without pregnancy, 4) neither regularly drank alcohol
nor smoked, 5) drug-free (including oral contraceptives
and over-the-counter drugs such as antioxidant agents),
6) without any history of cardio/cerebrovascular, thyr-
oid, kidney or liver diseases. The Jichi Medical Univer-
sity ethics committee approved the study and each
subject gave informed consent.
The BMI, seated SBP/DBP in the upper-arm, fasting
levels of blood glucose and lipids/lipoproteins, including
Lp(a) and oxLp(a), were measured. Glucose and lipids
were measured enzymatically, and serum C-reactive pro-
tein (CRP) was measured by a latex agglutination immu-
noassay. Plasma insulin was measured by an enzyme
immunoassay. Serum Lp(a) was measured by an ELISA
system (Shino-test Co. Ltd., Japan) [4]. Serum oxLp(a)
level was also quantified by a sandwich ELISA using the
oxLp(a)-specific monoclonal antibody (161E2) as both
the solid-phase antibody and the detecting capture anti-
body, as previously described [4]. This monoclonal anti-
body has been proven to react with only oxLp(a), not
native Lp(a) and LDL [4]. Especially, the antibody detects
a specific epitope peptide of 9 residues (Arg-Asn-Pro-
Asp-Ala-Val-Ala-Ala-Pro) from kringle-IV type-2 of apo
(a), which appears on the Lp(a) particle with oxidative
modification [4]. In the measurements, serum samples
were placed in each well of the Nunc-polystyrene micro-
plates coated with anti-oxLp(a) monoclonal antibody.
The plates were incubated for 1-hour at room tempera-
ture, and after washing, were incubated for 1-hour at
room temperature with anti-oxLp(a) monoclonal anti-
body labeled with peroxidase conjugate. After washing,
3,3’,5,5’-tetra-methylbenzidine was added to each well,
and the enzymatic reaction was thereafter carried out for
30-minutes at room temperature. After stopping the
reaction, the absorbance was read at 450 nm. The con-
centration of oxLp(a) was calculated based on the con-
centration of bovine serum albumin (BSA)-peptide that
contributed to 16 peptides per 1 molecule of BSA at a
standard [4]. The intraassay and interassay coefficients of
variation were 1.2% and 5.0%, respectively.
In this study, the cardio-ankle vascular index (CAVI)
[15] and carotid arterial intima-media thickness (IMT)
[16] were added as measures considered to reflect the
presence of atherosclerotic manifestations. The CAVI
was measured using oscillometric technology in the
supine position (Fukuda Denshi Co. Ltd., Japan) [15].
The IMT of the common carotid arteries was measured
ultrasonographically by a 10-MHz linear type B-mode
probe (Aloka Co. Ltd., Japan). The IMT, bilaterally mea-
sured in segments free of plaque (one at the thickest
site and another at two other points [1-cm upstream
and 1-cm downstream from the thickest site]), was aver-
aged in the 3-measurements.
The data are expressed as the mean ± standard devia-
tion or median plus interquartile range. The simple cor-
relations between oxLp(a) and the other variables were
examined by Pearson’s correlation test as well as a mul-
tiple linear regression analysis controlled for the vari-
ables. The values of TG, insulin, Lp(a) and oxLp(a) were
calculated after a log-transformation because of the
skewed distribution. A P < 0.05 was considered
significant.
Results
The subjects’ characteristics are presented in Table 1
and the correlations between oxLp(a) and the other
variables are listed in Table 2. A simple correlation
test showed in addition to a significantly positive cor-
relation between Lp(a) and oxLp(a), that glucose was
significantly and positively correlated with oxLp(a)
(Figure 1). On the other hand, glucose was non-signifi-
cantly correlated to Lp(a) (r =0 . 1 9 0 ,P =0 . 1 1 5 ) .O x L p
(a) was non-significantly correlated to CAVI (r =
0.196, P = 0.103) and IMT (r = - 0.041, P = 0.734). Lp
(a) was non-significantly correlated with either CAVI
Table 1 Clinical characteristics of the study subjects
Variable mean/median
Age (years) 22.2 ± 1.9
Body mass index (kg/m2) 20.1 ± 2.2
Systolic blood pressure (mmHg) 108.3 ± 8.2
Diastolic blood pressure (mmHg) 65.5 ± 6.0
LDL-cholesterol (mmol/L) 2.54 ± 0.59
HDL-cholesterol (mmol/L) 1.69 ± 0.24
Triglyceride (mmol/L) 0.63 (0.48-0.89)
Glucose (mmol/L) 4.85 ± 0.34
Insulin (μU/mL) 0.77 (0.58-0.90)
C-reactive protein (mg/dL) 0.06 ± 0.12
Lipoprotein(a) (mmol/L) 0.10 (0.06-0.27)
Oxidized lipoprotein(a) (nmol/L) 0.06 (0.03-0.13)
Cardio-ankle vascular index 5.4 ± 0.5
Carotid intima media thickness (mm) 0.40 ± 0.07
LDL, low-density lipoprotein; HDL, high-density lipoprotein. Data are shown as
the mean ± standard deviation or the median plus interquartile range.
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0.643). A multiple linear regression analysis adjusted
for age and the other cardiometabolic variables (BMI,
SBP, DBP, LDL-C, HDL-C, TG, glucose, insulin and
CRP) revealed only glucose levels to be independently
significantly and positively correlated with those of
oxLp(a).
Discussion
In this study, neither Lp(a) nor oxLp(a) were associated
with the measures of atherosclerotic manifestations such
as CAVI and IMT (these measures showed normal
levels). This result was expected, because our study
population was prepared to demonstrate a good state of
vascular health, in order to observe the relationship of
the blood cardiometabolic variables with oxLp(a) as sim-
ply as possible. Furthermore, we found a relatively good
correlation between Lp(a) and oxLp(a). This seems to be
plausible because native Lp(a) is a source of oxLp(a),
while an earlier study reported that in normotensives,
the correlation between Lp(a) and oxLp(a) might not
always be significant [4]. This may partly stem from the
differences in studied populations.
A more important finding is the significant positive
and independent correlation between glucose and oxLp
(a), not Lp(a), in the absence of defined hyperglycemia.
Although the correlation level was not necessarily
strong, this finding is nevertheless noteworthy due to
the fact that it was obtained from a strict study popula-
tion of the abovementioned otherwise healthy subjects.
Therefore, the present finding suggests that Lp(a) may
be oxidized with an increase in blood glucose concentra-
tion even within the normal range of glucose. Increased
blood glucose can promote the oxidative capacity of
modification of proteins and lipids [13,14]. This may
explain the previous observation that oxLDL exists with
high glucose concentrations [13,14,17]. Further studies
are required to determine whether lower blood glucose
concentrations are preferable even at normal glucose
levels in order to avoid the oxidization of Lp(a).
The detection methodology of oxLp(a) remains a deba-
table point. The respective ELISA systems, developed so
far, have different features [4,11,12]. One assay system
employs an antibody to LGE2 ([R]-acetyl-9[R]-formyl-12
[S]-hydroxy-5[Z],10[E]-heptadeca-dienoic acid)-protein
pyrroles, and the system may only examine an early stage
of oxidization of lipoproteins [11]. Another assay system
uses autoantibodies against oxLp(a), and these antibodies
possibly cover various epitopes [12]. One merit of our
system is that a peptide epitope, which appears in the
oxidative modification of Lp(a), is clearly defined to
detect oxLp(a) [4]. However, in addition to the fact that
the measureable amount of oxLp(a) is not very much in
this method, there is an opinion that the present system
may not distinguish the number of Lp(a) particles from
the number of modified kringle-IV repeats, because the
antibody used in this system reacts with the epitope on
kringle-IV type-2. Although earlier studies have shown
that there is less or, if possible, not so large influence of
the kringle-IV repeat numbers on the measured oxLp(a)
levels [4], we acknowledge the need for continuous stu-
dies on the association between apo(a) size isoform het-
erogeneity and oxLp(a) assay systems.
There are several limitations associated with this
study. The study population was relatively small. More-
over, it will be important to investigate various popula-
tions besides healthy populations as ours. The cross-
sectional design did not clearly elucidate the cause-and-
effect on the results. For instance, the positive correla-
tion between glucose and oxLp(a) may not only be the
result of oxidation of lipoproteins by glucose but also a
Table 2 Correlations of oxidized lipoprotein(a) with the
other variables
Variable r (P value) b (P value)
Age (years) 0.044 (0.719) - 0.012 (0.931)
Body mass index (kg/m2) - 0.012 (0.919) 0.026 (0.858)
Systolic blood pressure (mmHg) 0.035 (0.774) - 0.082 (0.647)
Diastolic blood pressure (mmHg) 0.139 (0.250) 0.175 (0.333)
LDL-cholesterol (mmol/L) - 0.060 (0.623) - 0.124 (0.381)
HDL-cholesterol (mmol/L) 0.173 (0.153) 0.174 (0.245)
Triglyceride (mmol/L) 0.058 (0.635) 0.147 (0.307)
Glucose (mmol/L) 0.313 (0.008)** 0.269 (0.048)*
Insulin (μU/mL) 0.138 (0.255) 0.049 (0.736)
C-reactive protein (mg/dL) 0.029 (0.810) 0.025 (0.847)
Lipoprotein(a) (mmol/L) 0.565 (< 0.0001)** -
LDL, low-density lipoprotein; HDL, high-density lipoprotein. r: Pearson’s
correlation coefficient between oxidized Lipoprotein(a) and another variable,
b: multiple linear regression coefficient in a multivariate analysis adjusted for
age and the following variables: body mass index, systolic blood pressure,
diastolic blood pressure, LDL-cholesterol, HDL-cholesterol, triglyceride, glucose,
insulin, C-reactive protein. Triglyceride, insulin, lipoprotein(a) and oxidized
lipoprotein(a) were calculated after a log-transformation, because of their
skewed distributions. Significance level: * P < 0.05, ** P < 0.01.
Figure 1 Correlation between glucose and oxidized lipoprotein
(a) (oxLp(a)).
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reportedly act as a scavenger (transporter) of oxidized
lipids derived from oxLDL [18]). In addition, the resi-
dual confounders that may affect the oxidization of lipo-
proteins, but were not included in our present study
(i.e., dietary factors), should also be considered. There-
fore, more studies with larger and various samples, pro-
spective designs and the inclusion of many confounders
are called for when conducting future studies.
Conclusions
In short, oxLp(a) showed a significantly positive correla-
tion with blood glucose among healthy young women.
Lipoprotein(a) may be oxidized with increased glucose
even within the normal glucose levels. Further research
is warranted to confirm this theory.
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